Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Overview
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Companies Involved in Therapeutics Development
Advent Therapeutics Inc
Avecho Biotechnology Ltd
Io Therapeutics Inc
Novartis AG
Orphagen Pharmaceuticals Inc
Orphanix GmbH
Ortho Dermatologics Inc
Polaryx Therapeutics Inc
Selphagy Therapeutics Inc
Sol-Gel Technologies Ltd
Sunny BioDiscovery Inc
TherapyX Inc
Toko Pharmaceutical Industries Co Ltd
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Drug Profiles
(benzoyl peroxide + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(benzoyl peroxide + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(gemfibrozil + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(TPX-6001 + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alitretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IRX-5183 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OR-812 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBD-073 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize RAR Alpha and RXR Alpha for Acute Promyelocytic Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RAR Alpha for Opthamology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamibarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tazarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Dormant Products
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Discontinued Products
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Product Development Milestones
Featured News & Press Releases
Jan 21, 2020: Sol-Gel announces presentation on Twyneo at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
Jan 13, 2020: Ortho Dermatologics announces publication of pivotal phase 3 data on ARAZLO (tazarotene) Lotion, 0.045% in the Jourl of Drugs in Dermatology (JDD)
Jan 12, 2020: Syros announces new update on SY-1425
Jan 08, 2020: Sol-Gel hosts investor call to discuss positive results from Twyneo phase 3 program in Acne Vulgaris
Dec 30, 2019: Sol-Gel announces positive top-line phase 3 trial results of Twyneo for the treatment of acne vulgaris
Dec 19, 2019: FDA approves Ortho Dermatologics’ ARAZLO (Tazarotene) lotion, 0.045%, for acne vulgaris
Oct 24, 2019: Syros Announces new data from phase 2 trial of SY-1425 in combition with azacitidine demonstrating high response rates, rapid onset of action and favorable tolerability profile in RARA-Positive Newly Diagnosed Unfit AML Patients
Oct 15, 2019: Bausch Health’s Ortho Dermatologics business to present data on tazarotene at The Fall Clinical Dermatology Conference
Oct 15, 2019: Bausch Health’s Ortho Dermatologics business to present data on acne drug tretinoin at The Fall Clinical Dermatology Conference
Aug 07, 2019: Ortho Dermatologics announces U.S. FDA filing acceptance for IDP-123 treatment for Acne Vulgaris in lotion form
Aug 01, 2019: Syros highlights key accomplishments and provides milestone update on SY-1425
Jul 09, 2019: GSK’s Alitoc becoming salvation treatment for chronic hand eczema patients
Apr 15, 2019: Sol-Gel Technologies announces 50% enrollment in pivotal phase III TWIN Program for the treatment of Acne Vulgaris
Jan 06, 2019: Syros provides update on its acute myeloid leukemia drug candidate SY-1425
Dec 17, 2018: Sol-Gel Technologies initiates pivotal phase III clinical program of TWIN for the treatment of acne vulgaris
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Advent Therapeutics Inc, H1 2020
Pipeline by Avecho Biotechnology Ltd, H1 2020
Pipeline by Io Therapeutics Inc, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Orphagen Pharmaceuticals Inc, H1 2020
Pipeline by Orphanix GmbH, H1 2020
Pipeline by Ortho Dermatologics Inc, H1 2020
Pipeline by Polaryx Therapeutics Inc, H1 2020
Pipeline by Selphagy Therapeutics Inc, H1 2020
Pipeline by Sol-Gel Technologies Ltd, H1 2020
Pipeline by Sunny BioDiscovery Inc, H1 2020
Pipeline by TherapyX Inc, H1 2020
Pipeline by Toko Pharmaceutical Industries Co Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020